GT Biopharma (GTBP) Income from Non-Controlling Interests (2012 - 2014)
GT Biopharma (GTBP) posted quarterly Income from Non-Controlling Interests of -$19000.0 for Q4 2014, down 58.33% year-over-year from -$45600.0 in Q4 2013, and down 2000.0% quarter-over-quarter from $1000.0 in Q3 2014.
GT Biopharma (GTBP) Income from Non-Controlling Interests (2012 - 2014) Analysis & Trends
GT Biopharma (GTBP) has reported Income from Non-Controlling Interests for 3 consecutive years, with -$19000.0 the latest figure, recorded in Q4 2014.
- In Q4 2014, Income from Non-Controlling Interests fell 58.33% year-over-year to -$19000.0; the TTM figure through Sep 2015 stood at -$19000.0 (down 72.73% YoY), while the FY2014 annual figure was -$16000.0, up 74.6% from the prior year.
- Income from Non-Controlling Interests eased to -$19000.0 in Q4 2014 per GTBP's latest filing, from $1000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $14000.0 in Q1 2013 and bottomed at -$62000.0 in Q4 2012.
- Historically, Income from Non-Controlling Interests has averaged -$14636.4 across 3 years, with a median of -$12000.0 in 2013.
- Annual changes were most pronounced in 2013 — Income from Non-Controlling Interests tumbled 206.67% — and 2014, when it jumped 102.17%.
- GT Biopharma's Income from Non-Controlling Interests stood at -$62000.0 in 2012, then soared by 80.65% to -$12000.0 in 2013, then tumbled by 58.33% to -$19000.0 in 2014.
- Business Quant data shows GTBP's Income from Non-Controlling Interests at -$19000.0 in Q4 2014, $1000.0 in Q3 2014, and -$1000.0 in Q2 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | -19,000.00 |
| Sep 30, 2014 | 1,000.00 |
| Jun 30, 2014 | -1,000.00 |
| Mar 31, 2014 | 1,000.00 |
| Dec 31, 2013 | -12,000.00 |
| Sep 30, 2013 | -46,000.00 |
| Jun 30, 2013 | -9,000.00 |
| Mar 31, 2013 | 14,000.00 |
| Dec 31, 2012 | -62,000.00 |
| Sep 30, 2012 | -15,000.00 |
| Jun 30, 2012 | -13,000.00 |